18f -氟吡唑PET心肌灌注显像研究进展

中华核医学与分子影像杂志 Pub Date : 2019-09-25 DOI:10.3760/CMA.J.ISSN.2095-2848.2019.09.013

Jiao Wang, Jianming Li, Shuai Li

{"title":"18f -氟吡唑PET心肌灌注显像研究进展","authors":"Jiao Wang, Jianming Li, Shuai Li","doi":"10.3760/CMA.J.ISSN.2095-2848.2019.09.013","DOIUrl":null,"url":null,"abstract":"PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. \n \n \nKey words: \nMyocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends","PeriodicalId":10099,"journal":{"name":"中华核医学与分子影像杂志","volume":"39 1","pages":"557-559"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of 18F-Flurpiridaz PET myocardial perfusion imaging\",\"authors\":\"Jiao Wang, Jianming Li, Shuai Li\",\"doi\":\"10.3760/CMA.J.ISSN.2095-2848.2019.09.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. \\n \\n \\nKey words: \\nMyocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends\",\"PeriodicalId\":10099,\"journal\":{\"name\":\"中华核医学与分子影像杂志\",\"volume\":\"39 1\",\"pages\":\"557-559\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华核医学与分子影像杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华核医学与分子影像杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.2095-2848.2019.09.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

PET心肌灌注成像（MPI）越来越多地用于冠状动脉疾病（CAD）的无创检测和评估。然而，常见的PET MPI试剂（15O-H2O、13N-NH3·H2O、82Rb）在临床上的广泛应用受到其固有缺陷的限制。18F Flurpiridaz的开发开辟了正电子血流显像剂的新领域。临床前和临床试验的初步结果表明，18F Flurpiridaz作为一种理想的PET MPI试剂具有重要的特性（高心肌摄取、高灌注缺陷分辨率、缓慢的心肌清除率、稳定的靶/非靶比值和定量心肌流量分析能力），具有良好的临床应用前景。本文综述了18F Flurpiridaz PET MPI的应用现状和进展。关键词：心肌灌注成像；正电子发射断层扫描；吡啶；氟放射性同位素；趋势

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress of 18F-Flurpiridaz PET myocardial perfusion imaging

PET myocardial perfusion imaging (MPI) is increasingly used in non-invasive detection and evaluation of coronary artery disease (CAD). However, the wide application of common PET MPI agents (15O-H2O, 13N-NH3·H2O, 82Rb) in clinic is limited by their inherent shortcomings. The development of 18F-Flurpiridaz has opened up a new field of positron blood flow imaging agents. Preliminary results of pre-clinical and clinical trials showed that 18F-Flurpiridaz has important properties (high myocardial uptake, high resolution of perfusion defect, slow myocardial clearance, stable target/non-target ratio, and the ability of quantitative myocardial flow analysis) as an ideal PET MPI agent, so it has a good clinical application prospect. In this paper, the present application and progress of 18F-Flurpiridaz PET MPI are reviewed. Key words: Myocardial perfusion imaging; Positron-emission tomography; Pyridazines; Fluorine radioisotopes; Trends

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华核医学与分子影像杂志核医学，分子影像

自引率

0.00%

发文量

5088

期刊介绍： Chinese Journal of Nuclear Medicine and Molecular Imaging (CJNMMI) was established in 1981, with the name of Chinese Journal of Nuclear Medicine, and renamed in 2012. As the specialized periodical in the domain of nuclear medicine in China, the aim of Chinese Journal of Nuclear Medicine and Molecular Imaging is to develop nuclear medicine sciences, push forward nuclear medicine education and basic construction, foster qualified personnel training and academic exchanges, and popularize related knowledge and raising public awareness. Topics of interest for Chinese Journal of Nuclear Medicine and Molecular Imaging include: -Research and commentary on nuclear medicine and molecular imaging with significant implications for disease diagnosis and treatment -Investigative studies of heart, brain imaging and tumor positioning -Perspectives and reviews on research topics that discuss the implications of findings from the basic science and clinical practice of nuclear medicine and molecular imaging - Nuclear medicine education and personnel training - Topics of interest for nuclear medicine and molecular imaging include subject coverage diseases such as cardiovascular diseases, cancer, Alzheimer’s disease, and Parkinson’s disease, and also radionuclide therapy, radiomics, molecular probes and related translational research.